Related Experiment Video

Updated: Jun 2, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

Yesid Alvarado1, Monica M Mita, Sushma Vemulapalli

  • 1Department of Hematology Oncology, Institute for Drug development, The University of Texas Health Science Center San Antonio, TX 78229, USA.

Targeted Oncology
|May 5, 2011
PubMed

Insights

The PI3K-Akt-mTOR pathway is crucial for cell growth. Rapalogs targeting mTOR show promise in cancer treatment, with ongoing research to optimize their use in various malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway regulates cell metabolism, growth, and proliferation.
  • mTOR is frequently overactive in various cancers, making it a key therapeutic target.
  • Sirolimus and its analogs (rapalogs) inhibit mTOR by forming a complex with FKBP12.

Purpose of the Study:

  • To review the PI3K-Akt-mTOR pathway's role in cancer biology.
  • To discuss the clinical trial results of rapalogs in treating different malignancies.
  • To identify future research directions for mTOR-targeted cancer therapy.

Main Methods:

  • Literature review of preclinical and clinical studies on rapalogs.
  • Analysis of clinical trial data for rapalogs in various cancer types.
  • Synthesis of information on pathway biology, drug mechanisms, and clinical outcomes.

Main Results:

  • Rapalogs have demonstrated clinical activity and are approved for specific cancers like kidney cancer and lymphoma.
  • The efficacy of rapalogs in other malignancies requires further investigation.
  • Optimal dosing, administration, and patient selection for mTOR/PI3K inhibition need further research.

Conclusions:

  • The PI3K-Akt-mTOR pathway is a significant target in oncology.
  • Rapalogs offer a therapeutic strategy for certain cancers, but broader application requires more research.
  • Future research should focus on personalized approaches to mTOR-targeted therapy.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...